Supriya Lifescience Q1 FY26: Revenue up 31% YoY, PAT down 31% YoY
SUPRIYA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.8 pts less than Nifty Microcap 250 and 2.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Supriya Lifescience posted Q1 FY26 revenue of Rs 1,897.47M, up about 31% YoY from Rs 1,450.74M. Profit after tax fell to Rs 240.43M from Rs 347.90M, a drop of around 31%, with EPS at Rs 2.99 versus Rs 4.32. Total expenses rose faster than sales, weighing on margins. The auditor gave an unmodified limited review. The company flagged that export material was intercepted and detained by Customs and recognized as sales but excluded from closing inventory.
Mixed quarter: strong top-line growth but sharp profit decline. Margin pressure and the Customs detention overhang may weigh on near-term sentiment.